Vaccines miss their mark in seasonal flu campaign

Each year vaccine makers create a cocktail of antigens designed to stand guard against the various versions of the flu making the rounds in winter. But this year the CDC concludes that most of the influenza B viruses in the U.S. aren't being stopped by the vaccine. Two of the three components in the vaccine aren't aimed the right B targets, it seems. The jab may, though, offer protection against the A versions in circulation.

"Most years, the prediction is very good," Joseph Bresee, an influenza epidemiologist at the CDC, tells the Washington Post. "In 16 of the last 19 years, we have had a well-matched vaccine."

- read the report from the Wall Street Journal

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Since the Warp Speed selections went public, experts have been wondering why some drugmakers were left off.

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.